Corrigendum: Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences
Bernardo Rossini(Istituto Tumori Bari), Attilio Guarini(Istituto Tumori Bari), Vanessa Innao, Mariano Lucignano, Roberto Massaiu, Gian Matteo Rigolin, Francesca Gaia Rossi, Luisa Verga(Azienda Ospedaliera San Gerardo), Maria Rosaria De Paolis(Istituto Nazionale di Fisica Nucleare, Sezione di Lecce), Felice Clemente(Istituto Tumori Bari), Nicola Cecchi, Giovanna Palumbo(Sapienza University of Rome), Stefan Hohaus
Cited by 3
Related Papers
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|216